These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9327888)

  • 41. Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss.
    Harvey DC; Lacan G; Tanious SP; Melega WP
    Brain Res; 2000 Jul; 871(2):259-70. PubMed ID: 10899292
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration.
    Truong JG; Hanson GR; Fleckenstein AE
    Eur J Pharmacol; 2004 May; 492(2-3):143-7. PubMed ID: 15178358
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains.
    Kilbourn M; Frey K
    Eur J Pharmacol; 1996 Jun; 307(2):227-32. PubMed ID: 8832225
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.
    Tillerson JL; Cohen AD; Philhower J; Miller GW; Zigmond MJ; Schallert T
    J Neurosci; 2001 Jun; 21(12):4427-35. PubMed ID: 11404429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease.
    Choi HJ; Lee SY; Cho Y; Hwang O
    Neurochem Int; 2005 Mar; 46(4):329-35. PubMed ID: 15707697
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vesicular amine transporter expression and isoform selection in developing brain, peripheral nervous system and gut.
    Schütz B; Schäfer MK; Eiden LE; Weihe E
    Brain Res Dev Brain Res; 1998 Mar; 106(1-2):181-204. PubMed ID: 9555003
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute exposure to aroclor 1016 or 1260 differentially affects dopamine transporter and vesicular monoamine transporter 2 levels.
    Richardson JR; Miller GW
    Toxicol Lett; 2004 Mar; 148(1-2):29-40. PubMed ID: 15019086
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum.
    Haycock JW; Becker L; Ang L; Furukawa Y; Hornykiewicz O; Kish SJ
    J Neurochem; 2003 Nov; 87(3):574-85. PubMed ID: 14535941
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preferential localization of a vesicular monoamine transporter to dense core vesicles in PC12 cells.
    Liu Y; Schweitzer ES; Nirenberg MJ; Pickel VM; Evans CJ; Edwards RH
    J Cell Biol; 1994 Dec; 127(5):1419-33. PubMed ID: 7962100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dopamine transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease.
    Harrington KA; Augood SJ; Kingsbury AE; Foster OJ; Emson PC
    Brain Res Mol Brain Res; 1996 Feb; 36(1):157-62. PubMed ID: 9011752
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice.
    Fumagalli F; Gainetdinov RR; Wang YM; Valenzano KJ; Miller GW; Caron MG
    J Neurosci; 1999 Apr; 19(7):2424-31. PubMed ID: 10087057
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons.
    Liang CL; Nelson O; Yazdani U; Pasbakhsh P; German DC
    J Comp Neurol; 2004 May; 473(1):97-106. PubMed ID: 15067721
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway.
    Jakowec MW; Nixon K; Hogg E; McNeill T; Petzinger GM
    J Neurosci Res; 2004 May; 76(4):539-50. PubMed ID: 15114626
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
    Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
    Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease.
    Sun M; Kong L; Wang X; Holmes C; Gao Q; Zhang GR; Pfeilschifter J; Goldstein DS; Geller AI
    Hum Gene Ther; 2004 Dec; 15(12):1177-96. PubMed ID: 15684695
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome.
    Meyer P; Bohnen NI; Minoshima S; Koeppe RA; Wernette K; Kilbourn MR; Kuhl DE; Frey KA; Albin RL
    Neurology; 1999 Jul; 53(2):371-4. PubMed ID: 10430428
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation.
    Xia XG; Schmidt N; Teismann P; Ferger B; Schulz JB
    J Neurochem; 2001 Oct; 79(1):63-70. PubMed ID: 11595758
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users.
    Wilson JM; Levey AI; Bergeron C; Kalasinsky K; Ang L; Peretti F; Adams VI; Smialek J; Anderson WR; Shannak K; Deck J; Niznik HB; Kish SJ
    Ann Neurol; 1996 Sep; 40(3):428-39. PubMed ID: 8797532
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cholinergic neurons and terminal fields revealed by immunohistochemistry for the vesicular acetylcholine transporter. I. Central nervous system.
    Schäfer MK; Eiden LE; Weihe E
    Neuroscience; 1998 May; 84(2):331-59. PubMed ID: 9539209
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum.
    Hettinger BD; Lee A; Linden J; Rosin DL
    J Comp Neurol; 2001 Mar; 431(3):331-46. PubMed ID: 11170009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.